A Non-randomised, Single-centre, Open-label phase I, single-dose study to evaluate the pharmacokinetics, mass balance, and metabolite patterns of [(14)C]-labeled Vilaprisan in healthy postmenopausal women
Latest Information Update: 16 Jan 2018
At a glance
- Drugs Vilaprisan (Primary)
- Indications Endometriosis; Uterine leiomyoma
- Focus Adverse reactions; Pharmacokinetics
- 16 Jan 2018 New trial record
- 12 Jan 2018 Results assessing phamacokinetics of Vilaprisan in EudraCT2014-004929-41 and EudraCT2013-000707-16 studies, published in the Clinical Pharmacokinetics